CASE CONTROL STUDY OF HIV+ AND HIV- LYMPHOMA (NHL) IN LOS ANGELES COUNTY (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CASE CONTROL STUDY OF HIV+ AND HIV- LYMPHOMA (NHL) IN LOS ANGELES COUNTY (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A1140 1992. Unique Identifier : AIDSLINE ICDB/92681869
Levine AM; Shibata D; Sullivan-Halley J; Nathwani B; Brynes R; Slovak M; Bauch S; Riley L; Weiss L; Levine P; et al; Univ. of Southern California Sch. of Medicine, Los Angeles, CA; 90033

Abstract: In an attempt to ascertain the epidemiologic and biologic correlates of NHL in HIV+ patients (pts), a prospective, population-based study was initiated in 1989. All cases of intermediate- or high-grade NHL are identified by the Cancer Surveillance Program, a population-based registry. Pathology is reviewed, an epidemiologic questionnaire is given and blood is analyzed for HIV, EBV, HHV-6, HLA, etc. Tumor tissue is studied for immunophenotype, genotype, oncogenes, HIV, EBV and karyotype. HIV+ NHL pts are compared to (1) HIV+ pts with AIDS, not NHL; (2) HIV+ asymptomatic pts; (3) HIV- NHL pts, and these are compared to (4) HIV- neighborhood controls. As of September 1991, 55 HIV+ NHL pts, 239 HIV- NHL and 181 control subjects are included. On pathologic evaluation, 82% of HIV+ NHL have been high-grade, B-cell types (small noncleaved or immunoblastic) vs 40% of HIV- NHL (p = 0.001). EBV titers over 1:1280 were found in 82% of HIV+ NHL vs 50% of HIV- NHL. Geometric mean titers of EBV-VCA were 1:880 in HIV- NHL; 1:1640 in HIV+ NHL and 1:1792 in HIV+ controls. Geometric mean titers of HHV-6 antibody were 1:177 in HIV- NHL, 1:156 in HIV+ NHL and 1:211 in HIV+ controls. By PCR and in situ hybridization of NHL tissue, EBV is present in 13/19 (68%) HIV+ NHL and 3/20 (15%) HIV- NHL. All studied cases of HIV+ and HIV- NHL have JH rearrangement by Southern blot. By PCR, t(14;18) is present in 0/17 HIV+ and 2/18 HIV- NHL. We conclude (1) By a prospective, population-based study, HIV+ NHL is comprised primarily of high-grade B-cell NHL, as opposed to HIV- NHL; (2) HHV-6 immune response does not appear to correlate with development of HIV+ NHL; (3) EBV genome is present in 68% of HIV+ NHL, but serologic analysis of EBV reveals no difference between HIV+ NHL and HIV+ controls; and (4) HIV+ NHL is genotypically monoclonal, without t(14;18).

Keywords: Case-Control Studies Herpesvirus 4, Human/ISOLATION & PURIF Human HIV/ISOLATION & PURIF HIV Infections/*EPIDEMIOLOGY Los Angeles/EPIDEMIOLOGY Lymphoma, AIDS-Related/*EPIDEMIOLOGY ABSTRACT
921030
M92A1039

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .